登录新浪财经APP 搜索【信披】查看更多考评等级 深圳精智达技术股份有限公司（证券代码：688627 证券简称：精智达）于2026年1月24日发布关于签订 日常经营重大合同的补充公告。公司此前于1月23日召开第四届董事会第八次会议，以9票同意、0票反 对、0票弃权审议通过了《关于签订日常经营重大合同的议案》。 公告指出，本次签订的合同属于公司控股子公司合肥精智达集成电路技术有限公司（以下简称"合肥集 成电路"）的日常经营行为。根据客户产线建设规划及公司产能安排，合同项下设备预计在3年内完成交 付，具体执行将依据交易双方实际签署的采购订单确定。该合同的履行预计将对公司2026年至2028年度 的经营业绩产生积极影响，公司将按照合同相关约定及企业收入确认原则，在相应会计期间确认收入， 最终数据以经会计师事务所审计的数据为准。 在风险提示方面，公告称合同双方虽均具有良好的履约能力，但在合同履行期间，若遭遇不可抗力或其 他因素，可能会影响合同的最终履行。同时，由于合同履行周期较长，存在原材料及人力成本上升导致 毛利率下降的风险。此外，合同总金额是基于客户预估采购数量确定的，具体执行需根据实际采购订 单，因此可能存在采 ...

Group 1 - Shoukai Co. achieved a signed area of 125.72 million square meters and a signed amount of 17.845 billion yuan in 2025 [1] - Tongda Hai expects a net loss for the year 2025 [2] - Jiuri New Materials' subsidiary has entered the trial production phase for a project with an annual capacity of 350 tons of hydroxy ketone [3] Group 2 - Jixin Technology's shareholder plans to reduce their stake by up to 1% [4] - Fulai New Materials received approval from the CSRC for a stock issuance [5] - Yaqi International plans to sign a strategic cooperation framework agreement with Zhongnong Holdings [6] Group 3 - Sanwei Co.'s controlling shareholder plans to transfer up to 5.10% of shares [7] - Lekai Film's subsidiary plans to invest 97.6675 million yuan in a TAC functional film production line [8] - China Power Construction's subsidiary signed two major contracts totaling approximately 15.589 billion yuan [9] Group 4 - Shunhao Co. plans to increase its investment in a subsidiary by 74.98 million yuan [10] - Jieneng Wind Power reported a cumulative power generation of 12.417 billion kWh in 2025, a year-on-year increase of 1.43% [11] - Zhongjian Technology's H-share issuance application has been accepted by the CSRC [12] Group 5 - Hendi Pharmaceutical expects a net profit decrease of 57.4% to 66.14% in 2025 [13] - Haopeng Technology anticipates a net profit increase of 113.69% to 141.09% in 2025 [14] - Lingang Co. expects a net loss of 1.45 billion to 1.67 billion yuan in 2025 [15] Group 6 - Chuan Investment Energy reported a cumulative power generation of 6.627 billion kWh in 2025, a year-on-year increase of 13.85% [16] - Tengyuan Cobalt expects a net profit increase of 50.02% to 69.87% in 2025 [17] - Huazhi Jie plans to repurchase shares worth 30 million to 50 million yuan [18] Group 7 - Opto has won a bid for a 120 million yuan project from GoerTek [19] - Shanghai Construction reported a new contract amount of 252.942 billion yuan in 2025, a year-on-year decrease of 34.98% [20] - Hangfa Control expects a net profit decrease of 52.02% to 58.02% in 2025 [22] Group 8 - Shimao Energy is planning a change in control and will continue to suspend trading [23] - Shenwan Hongyuan Securities received approval for a bond issuance of up to 60 billion yuan [24] - Jingjiawei signed a strategic cooperation letter of intent with Jing'an Technology [25] Group 9 - Pianzaihuang completed the first subject enrollment for a clinical trial of a new drug [26] - Placo's subsidiary received a new veterinary drug registration certificate [27] - Zhongli Co. plans to reduce its stake by up to 0.75% [28] Group 10 - Solar Energy received renewable energy subsidies of 3.318 billion yuan in 2025, a year-on-year increase of 142.9% [29] - Palm Co. has filed a lawsuit to recover 144 million yuan in project payments [30][31] - Yongjin Co. plans to invest 2.658 billion yuan in a new stainless steel project [32] Group 11 - BAIC Blue Valley plans to increase its stake by 14.5 million to 16.4 million yuan [33] - Lingyun Light's stock issuance application has been approved by the CSRC [34] - Hongbo New Materials expects a net loss in 2025 [35] Group 12 - Shanghai Pharmaceuticals received approval for the listing of a new antifungal drug [36] - Changjiang Electric reported a net profit of 34.167 billion yuan in 2025, a year-on-year increase of 5.14% [37] - Weilan Bio received a new veterinary drug registration certificate [38] Group 13 - Pingzhi Information's subsidiary is expected to win a procurement project worth approximately 37.5884 million yuan [39]

Group 1 - The core point of the article is that Honglu Steel Structure (002541.SZ) reported its operating performance for the first three quarters of 2025, highlighting a slight increase in new signed sales contracts compared to the previous year [1] - The total new signed sales contracts amounted to approximately RMB 22.267 billion, representing a year-on-year growth of 1.56% [1] - In terms of order composition, material orders accounted for RMB 22.240 billion, while engineering orders were RMB 0.027 billion [1] Group 2 - In the third quarter of 2025, the new signed sales contracts reached approximately RMB 7.887 billion [1]

Core Viewpoint - The company acknowledges that its operational performance is influenced by multiple factors such as market environment and industry competition, leading to a degree of uncertainty regarding growth [1] Group 1: Company Strategy - The company will continue to focus on its core business and enhance production and management practices [1] - The company aims to promote high-quality development through improved lean management and technological innovation [1] - The goal is to achieve better operational results to reward investors [1]

Core Insights - The company reported a total revenue of 2.138 billion yuan for the first half of 2025, a decrease of 10.85% compared to the same period last year [1] - Operating profit increased by 3.30% to 135 million yuan, while total profit rose by 6.56% to 133 million yuan [1] - Net profit attributable to shareholders decreased by 2.34% to 100 million yuan [1] Revenue Analysis - The decline in revenue is primarily attributed to a decrease in sales volume within the food business segment [1] - The overall revenue for the first half of 2025 was 2.138 billion yuan, reflecting a significant drop from the previous year [1] Profitability Factors - The increase in operating profit is mainly due to a reduction in raw material costs, which improved the product gross margin [1] - Cost control improvements in the pig farming segment contributed to a decrease in breeding costs [1]

Core Insights - Linhua Medical's total revenue for the first half of 2025 reached 456 million yuan, representing a year-on-year growth of 0.74% [1] - The company's net profit was 87.58 million yuan, showing a decline of 10.72% compared to the same period last year [1] - Earnings per share stood at 0.24 yuan, with a return on equity of 7.57% and operating cash flow per share of 0.2051 yuan [1] - The gross profit margin for sales was reported at 68.20% [1] Company Overview - Linhua Medical was established in 1996 and is located at No. 3 Weixin Road, Suzhou Industrial Park [1] - The company specializes in the research, production, and sales of clinical vascular drug delivery tools [1] - It has a registered capital of 360 million yuan, with Wu Wenyuan as the legal representative [1] Investment and Intellectual Property - Linhua Medical has invested in 19 companies and participated in 391 bidding projects [1] - The company holds 44 trademark registrations and 252 patent filings [1] - Additionally, it possesses 127 administrative licenses [1]

Core Viewpoint - Jintuo Co., Ltd. reported a steady growth in its operating performance for the first half of 2025, with significant increases in revenue and net profit, indicating a positive trend in the company's financial health [1][3]. Financial Performance - The company achieved an operating revenue of 369 million yuan, representing a year-on-year growth of 12.44% [1]. - The net profit attributable to shareholders reached 53 million yuan, showing a substantial year-on-year increase of 49.01% [1]. - The net profit margin improved from 10.35% in the first half of 2024 to 14.47% in 2025, an increase of 4.12 percentage points [3]. - The return on equity (ROE) for the first half of 2025 was 6.51%, up by 2.17 percentage points compared to the previous year [3]. Operational Efficiency - The inventory turnover days decreased to 132.35 days, down by 22.57 days from the first half of 2024, indicating improved inventory management efficiency [5]. - The net cash flow from operating activities was 79 million yuan, a 30% increase from 49 million yuan in the same period of 2024 [5]. - The company's debt-to-asset ratio rose to 35.67%, an increase of 5.47 percentage points year-on-year, indicating rising leverage [5]. Market Position - As of the first half of 2025, the number of institutional investors holding Jintuo shares decreased to 3, down from 18 in the same period of 2024, reflecting a decline in institutional interest [7]. - The company's market capitalization was reported at 6.051 billion yuan, significantly lower than its peak market value of 10.416 billion yuan in May 2015, requiring a 72.13% increase in stock price to reach that historical high [7].